When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Start Date: September 16, 2016
Expiration Date: September 15, 2019
Obesity is a currently a glaring public health concern because of its severe physiologic and economic implications. It has been reported that the healthcare burdens associated with obesity can be attenuated through weight loss. Moderate weight loss has been reported to improve cardiovascular health and reduce the incidence of type 2 diabetes mellitus. With this in mind, in 2013, the American Medical Association officially classified obesity as a disease, and the American Heart Association, American College of Cardiology, and The Obesity Society released new guidelines that recommend using a multifactorial approach in the treatment of obesity, with comprehensive lifestyle modification as the foundation for weight loss, and using adjunctive antiobesity pharmacotherapy and/or bariatric surgery when appropriate.
Although several antiobesity drugs are now available, they remain underutilized. This may be attributed to safety concerns, perceptions of limited efficacy, and a general unwillingness of patients and prescribers to view obesity as a disease. Cost is another barrier to widespread use; these agents are available only as brand name products and can be costly. Furthermore, many health insurers do not cover these agents. It is the purpose of this course to familiarize pharmacists with the current options for the management of obesity in adults, with an emphasis on pharmacotherapy, so that they may better educate other healthcare providers and patients about their selection, uses, and potential adverse effects.
Universal Activity Number (UAN) - 0607-0000-16-002-H01-P
Type of Activity - Knowledge
Topic Designator - 01
- Recognize when pharmacotherapy for overweight and obesity is indicated and the positive impact of weight loss on associated comorbid conditions.
- Review patients’ medications to reduce unhealthy weight gain and decrease the incidence of obesity and metabolic side effects.
- Recognize the efficacy and safety of pharmacotherapies for the treatment of obesity.
- Identify adverse events patients may experience while using pharmacotherapy as an adjunct to their obesity management.
Dhiren K. Patel, PharmD, CDE, BC-ADM, BCACP, is an associate professor of pharmacy practice in the School of Pharmacy – Boston at MCPHS University. He also maintains a clinical practice site at the VA Boston Healthcare System where he functions as a mid-level provider for a variety of chronic diseases, such as diabetes, hypertension, dyslipidemia, and obesity. He earned his PharmD from MCPHS University and received his postdoctoral residency training at the VA Boston Healthcare System. He is also board certified as an ambulatory care pharmacist (BCACP) and diabetes educator (CDE) and in advanced diabetes management (BC-ADM). Dr. Patel is one of the coauthors for the obesity and diabetes chapters in the Koda-Kimble and Young’s Applied Therapeutics textbook. This was the first clinical pharmacy textbook to be based on patient case histories. It is now in its 11th edition, has been translated into many languages, and is widely used in the United States and internationally. Dr. Patel has also been published in numerous peer-reviewed journals and delivered numerous presentations and lectures on obesity.
- Contact hours will be awarded for up to one (1) year from date of purchase or by the expiration date indicated above, whichever date comes first.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
- Dhiren K. Patel has disclosed that he is on the Speaker’s Bureau for Sanofi, Novo Nordisk, and Merck and that he is on the Advisory Board for Sanofi, Novo Nordisk, and Astra Zeneca. He has agreed to present content that is current, evidence based, and without bias.
- Kaelen Dunican has disclosed that she is on the Speaker’s Bureau for Novo Nordisk and on the Advisory Board for McNeil Consumer Healthcare. She has agreed to present content that is current, evidence based, and without bias.